SAN CARLOS, Calif.–(BUSINESS WIRE)–Dren Bio, a privately held, clinical-stage biotechnology company developing first-in-class antibody therapeutics for cancer, autoimmune, and other serious diseases, today announced the closing of an oversubscribed $350 million private financing. The round was co-led by Juvia Group and Lightspeed Venture Partners, with participation from an expanded syndicate of new investors including Mirae Asset Capital Life Science, General Catalyst, Cormorant Asset Managem